CN
Search Within
Y0001253
应用筛选条件
关键词:'Y0001253'
显示 1-30 共 76 条结果 关于 "Y0001253" 范围 论文
[A case with recurrent asystole due to breath-holding spells: successful treatment with levetiracetam].
S Sakaue et al.
No to hattatsu = Brain and development, 44(6), 496-498 (2012-12-18)
Amy Z Crepeau et al.
Expert review of neurotherapeutics, 10(2), 159-171 (2010-02-09)
Levetiracetam was approved by the US FDA in 1999 after failing the traditional screening tests for antiepileptic drugs. In the 10 years since its introduction, it has become one of the first-line antiepileptic agents and has been evaluated in small
Phenytoin or levetiracetam for seizure prophylaxis in TBI.
Larissa DeDea
JAAPA : official journal of the American Academy of Physician Assistants, 25(12), 11-11 (2013-04-23)
Brian Longo et al.
The Annals of pharmacotherapy, 43(10), 1692-1695 (2009-08-20)
To review data evaluating levetiracetam management of epilepsy during pregnancy. A literature search of PubMed (1966-June 2009) was performed using the terms pregnancy, epilepsy, levetiracetam, and anticonvulsants. Bibliographies of all articles retrieved were reviewed to identify additional relevant articles. All
[Successful treatment with levetiracetam in a case of Ohtahara syndrome caused by STXBP1 mutation].
S Yamashita et al.
No to hattatsu = Brain and development, 45(1), 64-66 (2013-04-19)
Amy J Halliday et al.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 20(1), 148-152 (2012-10-23)
Approximately one-third of people with epilepsy receive insufficient benefit from currently available anticonvulsant medication, and some evidence suggests that this may be due to a lack of effective penetration into brain parenchyma. The current study investigated the ability of biodegradable
Nitin K Sethi et al.
Drug metabolism and drug interactions, 28(2), 123-124 (2013-02-20)
Levetiracetam is a commonly used broad-spectrum anticonvulsant efficacious in both partial and generalized seizures. It has an extremely favorable side effect profile with few drug-drug interactions, low potential for hematological and hepatic toxicity, and thus has rapidly become the preferred
Marta Maschio et al.
Epileptic disorders : international epilepsy journal with videotape, 14(4), 388-397 (2012-12-19)
An open pilot study to evaluate the effect of pregabalin (PGB) as add-on therapy on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy (BTRE). We recruited 25 consecutive patients with BTRE and uncontrolled seizures. At
Helge Bjørnæs et al.
Epilepsy & behavior : E&B, 27(1), 40-48 (2013-02-05)
We performed a double-blind placebo-controlled crossover study of the effects of spike activity during sleep and when awake on learning, long-term memory, vigilance and behavior before and after treatment with levetiracetam in children with electrical status epilepticus during sleep. At
Mika H Martikainen et al.
Epileptic disorders : international epilepsy journal with videotape, 14(4), 438-441 (2012-12-19)
Epilepsy is a common manifestation of mitochondrial disease associated with mutations of the mitochondrial polymerase γ (POLG). Prognosis of mitochondrial epilepsy is often poor and there are few reports of successful treatment of POLG-related epilepsy. We describe a 26-year-old woman
Benjamin W Y Lo et al.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 38(3), 475-486 (2011-04-26)
New evidence suggests that levetiracetam may be as effective as traditional agents, with better safety profile. To synthesize evidence regarding efficacy and tolerability of levetiracetam as first line, adjunctive or prophylactic antiepileptic agent. Study Selection & Data Extraction: Eligible studies
Vincenzo Belcastro et al.
Brain & development, 33(4), 289-293 (2010-07-16)
Several new antiepileptic drugs (AEDs) have been introduced for clinical use recently. These new AEDs, like the classic AEDs, target multiple cellular sites both pre- and postsynaptically. The use of AEDs as a possible neuroprotective strategy in brain ischemia is
B Barrera-Bailón et al.
Epilepsy & behavior : E&B, 28(3), 413-425 (2013-07-23)
Epilepsy modeling is essential for understanding the basic mechanisms of the epileptic process. The Genetic Audiogenic Seizure Hamster (GASH:Sal) exhibits generalized tonic-clonic seizures of genetic origin in response to sound stimulation and is currently being validated as a reliable model
Konrad J Werhahn et al.
Epilepsia, 56(3), 450-459 (2015-02-17)
To compare the effectiveness of controlled-released carbamazepine (CR-CBZ) to levetiracetam (LEV) and to lamotrigine (LTG) in elderly patients with newly diagnosed focal epilepsy. Randomized, double-blind, parallel-group trial conducted between January 2007 and August 2011, in 47 ambulatory or hospital sites
Alberto Verrotti et al.
Paediatric drugs, 12(3), 177-186 (2010-05-22)
Levetiracetam is an antiepileptic drug that has been shown to be effective in various types of seizures, both partial and generalized. Although it is not yet well established because of the small number of studies, levetiracetam as both add-on therapy
Eugen Trinka et al.
Journal of neurology, neurosurgery, and psychiatry, 84(10), 1138-1147 (2012-08-31)
To compare the effectiveness of levetiracetam (LEV) with extended-release sodium valproate (VPA-ER) and controlled-release carbamazepine (CBZ-CR) as monotherapy in patients with newly diagnosed epilepsy. This unblinded, randomised, 52-week superiority trial (NCT00175903) recruited patients (≥16 years of age) with ≥2 unprovoked
Eileen Broomall et al.
Annals of neurology, 76(6), 911-915 (2014-11-05)
Super-refractory status epilepticus is a life-threatening condition. Resistance to benzodiazepine and barbiturate treatment for this disorder is thought to be due to internalization of synaptic γ-aminobutyric acid (GABA)A receptors, and withdrawal of benzodiazepines and barbiturates during treatment often triggers seizure
Gashirai K Mbizvo et al.
The Cochrane database of systematic reviews, 9(9), CD001901-CD001901 (2012-09-14)
Epilepsy is an important neurological condition and drug resistance in epilepsy is particularly common in individuals with focal seizures. In this review, we summarise the current evidence regarding a new antiepileptic drug, levetiracetam, when used as add-on treatment for controlling
Sabine Klein et al.
Neuropharmacology, 90, 53-62 (2014-12-03)
Despite more than 20 clinically approved antiepileptic drugs (AEDs), there remains a substantial unmet clinical need for patients with refractory (AED-resistant) epilepsy. Animal models of refractory epilepsy are needed for at least two goals; (1) better understanding of the mechanisms
Eric Dailly et al.
Therapie, 65(1), 67-70 (2010-03-09)
Levetiracetam is an anticonvulsant drug used to treat partial seizures, myoclonic seizures of juvenile myoclonic epilepsy and primary generalized tonic-clonic seizures. A review of the literature with an evidence-based medicine method highlighted parameters (age, renal failure, pregnancy, combination with other
Hai-Dun Yan et al.
Brain research bulletin, 90, 142-148 (2012-10-31)
Levetiracetam (LEV) is a widely used antiepileptic agent for partial refractory epilepsy in humans. LEV has unique antiepileptic effects in that it does not inhibit electroshock- or pentylenetetrazol-induced convulsion, but does inhibit seizures in kindling animal and spontaneously epileptic rat
Drug-drug interaction between methotrexate and levetiracetam in a child treated for acute lymphoblastic leukemia.
Anne-Sophie Parentelli et al.
Pediatric blood & cancer, 60(2), 340-341 (2012-11-07)
Jingdong Chao et al.
Advances in therapy, 32(3), 270-283 (2015-03-17)
The purpose of the present study was to investigate the traceability of adverse events (AEs) for branded and generic drugs with identical nonproprietary names and to consider potential implications for the traceability of AEs for branded and biosimilar biologics. Adverse
Bong Su Kang et al.
Epileptic disorders : international epilepsy journal with videotape, 15(3), 302-310 (2013-08-29)
To evaluate the long-term efficacy and safety of levetiracetam based on a large population of patients in a tertiary epilepsy centre. All patients who received levetiracetam at the Seoul National University Hospital between January 2007 and March 2009 were evaluated.
D Consoli et al.
Cerebrovascular diseases (Basel, Switzerland), 34(4), 282-289 (2012-11-07)
Strokes are the leading cause of epileptic seizures in adults and account for 50% of seizures in those over the age of 65 years. The use of antiepileptic drugs to prevent recurrent poststroke seizures is recommended. One hundred and twenty-eight
Levetiracetam-associated acute pancreatitis in an adolescent with autism: a case report.
Daniel M Almeida et al.
Pancreas, 42(1), 177-178 (2012-12-21)
Fawzi A Babtain
Clinical neuropharmacology, 35(4), 201-202 (2012-07-19)
Levetiracetam was approved for generalized and partial epilepsy in pediatric and adult population. It is also an effective antimyoclonus, but the evidence only supports its use as an adjunctive agent along with other antiepileptic drugs, such as sodium valproate, and
S Svalheim et al.
Acta neurologica Scandinavica. Supplementum, (196)(196), 11-15 (2012-12-05)
The aim of the study was to investigate immunoglobulin levels in patients with epilepsy using the antiepileptic drugs (AED) levetiracetam (LEV), carbamazepine (CBZ), or lamotrigine (LTG). A total of 211 patients and 80 controls (age: 18-45 years) of both genders
Dong Wook Kim et al.
Epilepsia, 54(10), e146-e149 (2013-08-29)
Although it is well documented that long-term therapy with older antiepileptic drugs (AEDs) leads to an increase in risk for atherosclerosis, there has been only limited information regarding the vascular risk in patients who are treated with new AEDs. We
What is the relative value of the standard anticonvulsants: Phenytoin and fosphenytoin, phenobarbital, valproate, and levetiracetam?
Eugen Trinka
Epilepsia, 50 Suppl 12, 40-43 (2009-11-28)
1/3